Cargando…
Targeting of CD163(+) Macrophages in Inflammatory and Malignant Diseases
The macrophage is a key cell in the pro- and anti-inflammatory response including that of the inflammatory microenvironment of malignant tumors. Much current drug development in chronic inflammatory diseases and cancer therefore focuses on the macrophage as a target for immunotherapy. However, this...
Autores principales: | Skytthe, Maria K., Graversen, Jonas Heilskov, Moestrup, Søren K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432735/ https://www.ncbi.nlm.nih.gov/pubmed/32752088 http://dx.doi.org/10.3390/ijms21155497 |
Ejemplares similares
-
Drug Trafficking into Macrophages via the Endocytotic Receptor CD163
por: Graversen, Jonas Heilskov, et al.
Publicado: (2015) -
Specific targeting of CD163(+) TAMs mobilizes inflammatory monocytes and promotes T cell–mediated tumor regression
por: Etzerodt, Anders, et al.
Publicado: (2019) -
Targeting the Hemoglobin Scavenger receptor CD163 in Macrophages Highly Increases the Anti-inflammatory Potency of Dexamethasone
por: Graversen, Jonas H, et al.
Publicado: (2012) -
Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes
por: Svendsen, Pia, et al.
Publicado: (2016) -
Anti-CD163-dexamethasone protects against apoptosis after ischemia/reperfusion injuries in the rat liver
por: Møller, Lin Nanna Okholm, et al.
Publicado: (2015)